Birchview Capital’s Elicio Therapeutics ELTX Stock Holding History

Birchview Capital’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,439	Closed	-$32K	–	55
2023 Q1	$32K	Hold	5,439	–	–	0.03%	54
2022 Q4	$44K	Hold	5,439	–	–	0.03%	54
2022 Q3	$50K	Hold	5,439	–	–	0.04%	57
2022 Q2	$62K	Hold	5,439	–	–	0.05%	56
2022 Q1	$115K	Hold	5,439	–	–	0.08%	57
2021 Q4	$158K	Hold	5,439	–	–	0.1%	62
2021 Q3	$531K	Sell	5,439 -623	-10%	-$67.3K	0.36%	40
2021 Q2	$1.94M	Hold	6,062	–	–	1.16%	15
2021 Q1	$1.09M	Buy	+6,062	New	+$1.17M	0.65%	26

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Birchview Capital's ELTX Position: Q2 2023 in Review

Birchview Capital sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 5,439 shares — an estimated $32K sold.

Birchview Capital first reported a position in ELTX in Q1 2021 and held it in 9 quarters. The position peaked at $1.94M in Q2 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

Birchview Capital reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
Birchview Capital sold 5,439 Elicio Therapeutics shares in Q2 2023, an estimated $32K.
Birchview Capital first reported a position in Elicio Therapeutics in Q1 2021 and held it in 9 quarters.
Birchview Capital's Elicio Therapeutics position peaked at $1.94M in Q2 2021.
15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Birchview Capital's 13F filing for Q2 2023, filed 8 Aug 2023.